Myocardial perfusion imaging in women for the evaluation of stable ischemic heart disease—state-of-the-evidence and clinical recommendations
This document from the American Society of Nuclear Cardiology represents an updated consensus statement on the evidence base of stress myocardial perfusion imaging (MPI), emphasizing new developments in single-photon emission tomography (SPECT) and positron emission tomography (PET) in the clinical evaluation of women presenting with symptoms of stable ischemic heart disease (SIHD). The clinical evaluation of symptomatic women is challenging due to their varying clinical presentation, clinical risk factor burden, high degree of comorbidity, and increased risk of major ischemic heart disease events. Evidence is substantial that both SPECT and PET MPI effectively risk stratify women with SIHD. The addition of coronary flow reserve (CFR) with PET improves risk detection, including for women with nonobstructive coronary artery disease and coronary microvascular dysfunction. With the advent of PET with computed tomography (CT), multiparametric imaging approaches may enable integration of MPI and CFR with CT visualization of anatomical atherosclerotic plaque to uniquely identify at-risk women. Radiation dose-reduction strategies, including the use of ultra-low-dose protocols involving stress-only imaging, solid-state detector SPECT, and PET, should be uniformly applied whenever possible to all women undergoing MPI. Appropriate candidate selection for stress MPI and for post-MPI indications for guideline-directed medical therapy and/or invasive coronary angiography are discussed in this statement. The critical need for randomized and comparative trial data in female patients is also emphasized.
KeywordsStable ischemic heart disease imaging women ASNC consensus statement
American Society of Nuclear Cardiology
Appropriate use criteria
Coronary artery calcium
Coronary artery disease
Coronary flow reserve
Coronary microvascular dysfunction
Exercise treadmill testing
Guideline-directed medical therapy
Left ventricular ejection fraction
Myocardial perfusion imaging
Positron emission tomography
Stable ischemic heart disease
Single-photon emission tomography
The evidence base regarding sex differences in cardiovascular imaging is substantial with several recent reviews on the subject.1, 2, 3, 4, 5, 6 This consensus statement from the American Society of Nuclear Cardiology (ASNC) seeks to provide a comprehensive update to the evidence regarding the utility of nuclear cardiology to evaluate women presenting with symptoms consistent with stable ischemic heart disease (SIHD).7 The term SIHD refers to stable patients with suspected or documented myocardial ischemia. This may occur in the presence or absence of obstructive coronary artery disease (CAD), typically defined as luminal narrowing of 70% or greater in the epicardial vessels. Ischemic heart disease events include sudden cardiac death and acute coronary syndromes, including unstable angina leading to emergent or urgent coronary revascularization. This document supersedes a prior ASNC statement on the value of stress myocardial perfusion imaging (MPI) in women8 and aims to represent the use of imaging within the evaluation for SIHD, including testing among those with nonobstructive and obstructive CAD. The current statement highlights the specific evidence supporting the widespread use of MPI single-photon emission tomography (SPECT), and the growing data supporting expanded use of MPI positron emission tomography (PET) in the evaluation of symptomatic women for SIHD. Several prior clinical practice guidelines and consensus statements have been published on this topic.5,7
Appropriate delineation and utilization of guideline-directed care for women with SIHD remain a vital goal.7,9 In the last three decades, the case fatality rates for cardiovascular disease (CVD) have been substantially higher for women compared to men.10 Part of the excess mortality in women has been related to under-testing and under-treatment of at-risk females.11,12 With increased awareness and a focus on guideline-directed strategies for care, there have been recent decreases in CVD mortality; yet these declines have been far less for women than men.13 The lack of progress bettering the lives of at-risk women is disappointing and suggests opportunities for an enhanced diagnostic strategy of care that may improve detection and clinical outcomes for female patients with SIHD. The current document reviews the latest evidence on the role of nuclear cardiology techniques in the diagnostic and prognostic evaluation of women. The following topics are included for discussion: (a) appropriate use of MPI in women; (b) MPI with SPECT and PET; (c) MPI as gatekeeper to quality testing patterns in women, including strategies for radiation dose reduction; (d) recent randomized trial evidence of MPI versus other approaches for the evaluation of suspected SIHD; and (e) future directions in clinical research for assessing SIHD in women with and without obstructive CAD.
Appropriate Use of MPI in Women
SPECT MPI in Women for Evaluation of SIHD
SPECT MPI is a mature technique that is widely used for the evaluation of suspected or known CAD. In women, SPECT MPI is highly accurate to diagnose flow-limiting (i.e., obstructive) CAD and to stratify risk of IHD events. Advancements in SPECT technology with high count rate imaging, low radiation doses, and theoretically, the potential to quantify myocardial blood flow,18 are likely to further advance the utility of SPECT MPI in women.
Diagnostic Accuracy of SPECT MPI in Women
For patients with intermediate pretest SIHD risk, noninvasive imaging has a well-established role in the diagnosis of CAD.9 Radionuclide MPI with SPECT using either exercise or pharmacologic stress testing remains the most common form of stress imaging in the evaluation of patients with known or suspected CAD, and represents a robust approach for diagnosing flow-limiting CAD. A 2012 report from the Agency for Healthcare Research and Quality19 addressed the diagnostic accuracy of noninvasive testing techniques as compared with coronary angiography specifically in symptomatic women with suspected SIHD. In a subgroup analysis of 14 studies of 1,000 women with no known CAD, the diagnostic sensitivity was 81% and specificity was 78% for detecting obstructive CAD.19 In a subsequent analysis of 30 studies evaluating women with known or suspected CAD, SPECT MPI had a sensitivity of 82% and specificity of 81% for detecting obstructive CAD.20
A strength of SPECT is the availability of robust software programs for the interpretation of MPI. Women have a smaller heart size compared to men, with resultant higher image blurring and, potentially, a lower sensitivity to detect obstructive CAD. Women also have higher left ventricular ejection fraction (LVEF),21 and may have higher normal limits of transient ischemic dilation (TID) ratio compared to men.22 As such, sex-based normal limits should be used for reporting of LVEF and volumes. Using sex-based normal limits and software interpretation, diagnostic accuracy for detection of obstructive CAD was high without significant sex differences in a multicenter study of SPECT MPI.23
Attenuation correction represents an important consideration to improve the specificity and normalcy rates of SPECT MPI, particularly in women with high likelihood of attenuation from breast tissue and/or high body mass indices (BMI). Correction for attenuation can be achieved through a combination of (1) supine and prone imaging, (2) supine and upright imaging, or (3) direct correction using either line sources or computed tomography (CT). Typically, overall sensitivity does not increase with attenuation-corrected SPECT MPI.24, 25, 26, 27, 28 In a study of combined supine and prone imaging in normal, overweight, and obese women, Berman et al.29 showed that specificity and normalcy rates were unaffected by BMI, whereas sensitivity declined in overweight and obese women compared to normal weight women. In a subsequent study of 459 women evaluated with a quantitative method, Slomka et al.30 reported improved specificity and normalcy with no loss in sensitivity when combined supine and prone imaging was performed using a standard Anger camera. Ben-Haim et al.31 showed that addition of an upright acquisition to the standard supine acquisition using a solid-state cadmium zinc telluride (CZT) camera reclassified 69% of equivocal scans in males and 77% of equivocal scans in females as either normal or abnormal. Furthermore, the perceived need for rest scanning in women was reduced by more than 50%. Direct correction for bodily attenuation is possible using either line sources or CT. Attenuation correction has been shown to result in gender-independent distributions of tracer over the entire myocardium,32 to improve interpretive certainty, and to reduce the need for rest images when the stress study is acquired first.33 Collectively, these techniques have been proven to be of value, and none require additional dosages of radionuclide. As such, this consensus statement encourages consideration of one of these approaches during SPECT MPI, particularly when imaging is performed in women with large breasts, breast implants, and/or high BMIs.
In addition, unique sex differences in the development of atherosclerosis and obstructive CAD may underlie some observed differences in test performance between women and men. There is an increasing recognition that coronary microvascular dysfunction (CMD) with or without epicardial CAD is prevalent in women.34,35 In this setting, SPECT MPI may have lower apparent specificity for women as compared to men, especially when obstructive epicardial CAD is used as the reference standard for diagnostic accuracy of MPI.
Exercise versus Pharmacological Stress Testing in Women
Exercise stress is preferred over pharmacological stress for SPECT MPI in women, except among individuals with left bundle branch block (LBBB) or ventricular pacing, or in those incapable of performing adequate exercise, in whom vasodilator stress is preferred.36 Exercise stress is physiologic and provides clinical, hemodynamic, and ECG data, which enable important diagnostic and prognostic information. However, among women, exercise-induced ST depression in the absence of CAD has been described in relation to changes in estrogen levels during the menstrual cycle37 or from menopausal hormone therapy38 and has been associated with lower diagnostic accuracy when compared to men.39 In a study of 2,994 asymptomatic women, measures of reduced functional capacity (low exercise capacity, low heart-rate recovery, and not achieving target heart rate) rather than ischemic ST depression provided prognostic value.40 As discussed later, results of the multicenter randomized WOMEN (What is the Optimal Method of Ischemia Elucidation in WomeN?) trial indicated no advantage of ETT with MPI over ETT alone in low-intermediate risk women able to exercise.15 In contrast, in women with intermediate–high pretest SIHD risk, the diagnostic accuracy to detect obstructive CAD is greater for ETT with SPECT MPI than for ETT alone (MPI, sensitivity 78% [95% CI 72% to 83%] versus ETT only, sensitivity 61% [95% CI 54% to 68%]).41 An alternative strategy includes adding SPECT MPI following an intermediate risk ETT.
Nonetheless, exercise capacity is commonly limited in women referred for SPECT MPI, who are typically older and have significant comorbidities. These patients may need graded exercise stages that increase the metabolic equivalents of work in a more gradual manner than in the commonly used Bruce protocol. In women who are unable to exercise adequately, pharmacological stress testing provides an alternative to exercise stress testing. Among men and women with normal adenosine SPECT MPI, women more frequently manifest ischemic ECG changes.42 Despite a normal adenosine SPECT MPI, rates of CAD death and nonfatal myocardial infarction (MI) were higher in women with ischemic ECG changes compared to those without ischemic ECG changes.42,43
It is unlikely that differences in the dosing regimen of vasodilators significantly impact test sensitivity of pharmacological stress MPI among female and male patients. Although adenosine and dipyridamole are weight-based infusions and, in general, women receive a smaller absolute dose of adenosine or dipyridamole compared to men, adenosine44 and dipyridamole45 SPECT are similarly diagnostically accurate in women and men. In addition, although regadenoson is a nonweight-based injection of 400 mcg, integrated data from the two-phase 3 ADenoscan Versus regAdenosoN Comparative Evaluation for MPI (ADVANCE MPI) trials, which included 30% women, demonstrated that regadenoson as compared to adenosine was safe, well-tolerated, and similarly effective in women as in men.46
Data support that adjustment for pretest likelihood of CAD improves the diagnostic accuracy of SPECT MPI in women, resulting in no significant differences in women compared to men.47 In a study using vasodilator stress and technetium-99m (99mTc) MPI, the sensitivity, specificity, and normalcy rates for detection of obstructive CAD were high at 93%, 78%, and 88%, respectively; sensitivity and specificity did not vary significantly by pretest likelihood of CAD. But, as in men, test sensitivity in women was lower for detection of significant luminal narrowing in the left circumflex territory relative to the left anterior descending or right coronary territories.44 Test performance was high likely due to better image quality with 99mTc MPI (higher energy photons and gated imaging) as compared to thallium (201Tl). The value of 99mTc MPI and gated SPECT is highlighted by data from another study wherein the specificity of MPI to exclude obstructive epicardial CAD improved from 67.2% with 201Tl MPI to 84.4% with 99mTc MPI, and to 92.2% with 99mTc MPI combined with gated SPECT.48 In high-risk women, exercise perfusion variables identified high-risk CAD better than ETT variables alone.49
Other studies have reported sex differences in the diagnostic accuracy of SPECT MPI, with lower accuracy for SPECT MPI in women compared to men.50, 51, 52 As already discussed, this lower diagnostic accuracy among women has been variably attributed to multiple epidemiological, biological, and imaging factors such as imaging of women with a low pretest likelihood of obstructive CAD, reduced exercise capacity and lower maximal heart rates achieved during exercise (women referred for testing are generally older than men), higher prevalence of CMD and single vessel CAD wherein SPECT MPI is known to have a reduced sensitivity, smaller cardiac size, and anterior wall attenuation artifacts from breast tissue.
Risk Stratification of Women with SPECT MPI
SPECT MPI plays a pivotal role in risk stratification of women with known or suspected CAD.21,53, 54, 55, 56 In a large meta-analysis, after a mean follow-up of 36 months, the prognostic value of a normal SPECT MPI among women was excellent with 99% event-free survival, and similar to that of men.57 A normal SPECT MPI in the setting of a normal stress ECG portended excellent survival free of future CAD death or MI.58 In contrast, the presence of abnormal ST segment changes with a normal MPI was associated with an elevated risk of major adverse cardiac events. Abnormal SPECT MPI provides incremental risk stratification over ETT variables alone. Hachamovitch et al.53 showed in a study of 4,136 patients (33.7% women) that MPI variables provided incremental prognostic value over ETT variables for women and men followed over a mean of 20 ± 5 months. Mild, moderate, or severely abnormal SPECT MPI scans were associated with graded increases in adverse CAD events in women. MPI findings provided better discrimination of risk, identifying higher risk women compared to higher risk men (area under the receiver operating characteristics curve = 0.84 ± 0.03 versus 0.71 ± 0.03, P < 0.0005).53
A large body of literature supports the excellent prognostic value of normal stress-only SPECT imaging when attenuation correction is employed.62,63 In one pooled analysis (of 22,443 patients, 46.5% with a stress-only study), a normal stress-only study was associated with an annual cardiac event rate of 0.7%.58 This risk is low and comparable to that associated with a normal rest and stress MPI. The study of Chang et al.62 showed that a normal stress-only scan conferred the same low likelihood of events in women as in men.
Hybrid SPECT with CT Imaging
An evolving body of literature supports the utility of SPECT MPI combined with coronary artery calcium (CAC) scoring64, 65, 66, 67, 68, 69, 70 or coronary CT angiography (CCTA) to assess for the presence of stress-induced myocardial ischemia along with coexistent calcified and noncalcified atherosclerotic plaque. CAC can be visualized not only on a dedicated high dose, breath-hold CT scan, but also on the non-gated low dose CT scan obtained for attenuation correction, although sensitivity for detecting CAC may be reduced in the latter.71
Studies incorporating CAC scoring into SPECT imaging highlight three key points. First, a CAC score of 0 is associated with low rates of ischemia among symptomatic individuals (ischemia was noted in <3% of individuals with CAC score <100)64,68 and in asymptomatic diabetic individuals.67 In a recent trial of CAC followed by selective downstream testing only in those with detectable CAC,72 downstream testing was reduced by 40% and no CAD events were observed through one year of follow-up among those with a CAC score of 0. Other literature, however, suggests that the risk of patients with a CAC of 0 is heterogeneous, and driven by underlying clinical risk.73 Second, the frequency of ischemia increases with increasing CAC scores. Among symptomatic patients, >25% of individuals with CAC score ≥1000 demonstrated ischemia.68 Third, as many as 75% of individuals with normal MPI may have underlying calcified coronary atherosclerosis.68 A high CAC score with normal MPI portends a low risk of short-term events (i.e., within the first 3 years), but a higher risk of events in the intermediate- to long-term (>3 years).64,67,69,70 While most of the above studies included a large predominance of men, a recent large study compared the prognostic value of CAC scoring among asymptomatic, low-intermediate risk patients, of whom 45.4% were women.74 In this study, women compared to men were older, had a greater prevalence of CAC, and a higher 15-year mortality. Although the literature on CAC scoring combined with MPI in symptomatic women is limited, these findings support the addition of CAC in women to improve risk stratification beyond traditional algorithms.
Several investigators have evaluated simultaneous or sequential MPI and CCTA to identify the hemodynamic significance of coronary stenoses detected on CTA, particularly for indeterminate stenoses.75, 76, 77 Stress-only MPI with CTA has also been proposed as a low-radiation dose protocol with comprehensive ischemia and atherosclerosis imaging.78 An abnormal SPECT MPI along with abnormal CTA was associated with an annual death rate of 6%, and independently associated with a high risk of death and MI (P < 0.005).79 However, to date, the results of these studies do not identify any patient subgroup preferentially benefiting from the use of combined MPI and coronary atherosclerosis imaging protocols, and limited data specific to women are available.
Solid-State Detector SPECT MPI
Novel solid-state detector cardiac SPECT scanners demonstrate vastly improved count performance and superior energy discrimination compared to conventional NaI detector SPECT scanners.80 Solid-state scanners also include advanced reconstruction methods of iterative reconstruction, noise reduction, and resolution recovery that enhance image quality and speed of acquisition, and reduce radiation dose.80 Upright imaging (feasible with some scanners) may change patterns of breast attenuation or minimize attenuation artifacts in women. Dynamic tomographic SPECT imaging is feasible with some of these scanners, and under investigation for quantification of myocardial perfusion reserve,81 which may be useful to identify CMD. Enhancements allowing for high efficiency and improved image quality make solid-state detector SPECT particularly valuable for MPI in women. Although limited literature exists on the diagnostic accuracy of this technology in women or in general,82, 83, 84 one study showed that the diagnostic accuracy of solid-state 99mTc-SPECT is high in women (area under receiver operating characteristic [ROC] curve, 0.822 [95 % CI 0.685 to 0.959] and comparable to diagnostic accuracy in men [overall ROC area 0.884, 95 % CI 0.836 to 0.933]).84
SPECT Summary Statement
Prompt evaluation of anginal symptoms in women is critical to initiate guideline-directed strategies of care aimed at improving IHD outcomes. SPECT MPI is widely available with high diagnostic and prognostic accuracy for women and men. Although ETT alone may suffice in the evaluation of lower risk women with good functional capacity and a normal rest ECG, SPECT MPI is particularly effective for identification of women at high risk of IHD events. Strategies are available to address women-specific attenuation patterns, such as those from large breasts or breast implants. Stress-first (i.e., stress-only when normal) imaging with attenuation correction is as effective in women as in men, and should be preferentially utilized when appropriate. Solid-state detector SPECT technology holds promise to further enhance the utility of SPECT MPI for women with improved throughput, superior image quality, and potentially, the ability to quantify myocardial blood flow for the assessment of diffuse CAD and CMD.
PET MPI in Women for Evaluation of SIHD
Over the last decade, radionuclide MPI with PET has become a powerful tool for the diagnosis and risk stratification of patients with known or suspected CAD.3,85 Here, we describe the maturing role of PET imaging in women, particularly in the evaluation of SIHD. PET imaging offers distinct advantages in the evaluation of myocardial ischemia in women, such as (1) improved diagnostic accuracy, (2) low-radiation exposure using short-lived radiopharmaceuticals, and (3) the ability to quantify myocardial blood flow and coronary flow reserve to diagnose ischemia, even in the absence of obstructive CAD. As such, cardiac PET MPI stands to play a unique role in defining the diagnosis and prognosis of women with SIHD, while also guiding new treatment strategies for their more prevalent cardiovascular disease phenotypes.
Diagnostic Accuracy of PET MPI in Women
For symptomatic intermediate risk women who are capable of exercising and have an interpretable resting ECG, the ETT remains the recommended initial diagnostic test.5 For the sizeable number of patients in whom the addition of imaging is indicated, there are unique characteristics of PET that make it particularly appealing for the evaluation of women. PET MPI has excellent diagnostic performance for the detection of CAD and is now performed in over 200 medical centers in the United States and a growing number of centers worldwide.85 Relative to conventional stress testing with SPECT MPI or echocardiographic regional wall motion assessment, PET MPI provides images of high diagnostic quality and improved diagnostic accuracy, with an average sensitivity of 90% and specificity of 89% for detecting angiographically significant coronary stenoses.86 Recent meta-analyses have confirmed incremental improvement in diagnostic accuracy with PET relative to SPECT for the diagnosis of obstructive CAD,87,88 with an area under the ROC curve of 0.95 and 0.90 for PET and SPECT (P < 0.0001).
Several technical advantages account for the enhanced diagnostic ability of PET. These include: (1) routine measured (depth-independent) attenuation correction, which decreases false positives and thereby increases specificity; (2) high spatial and contrast resolution (heart-to-background ratio), which allows improved detection of small perfusion defects, thereby decreasing false negatives and increasing sensitivity; (3) the use of short-lived radiopharmaceuticals, which translate into very low-radiation doses as well as fast sequential assessment of rest/stress perfusion imaging, which allows for high laboratory efficiency and patient throughput; and (4) high temporal resolution, which allows for fast dynamic imaging of tracer kinetics and makes possible the absolute quantification of myocardial perfusion (in mL/min/g of tissue).85 In women, these advantages may be especially relevant given: (1) the risk of false positives due to attenuation from breast or general adipose tissue in those with high BMI; (2) the risk of false negatives due to partial volume effects, which are amplified in small left ventricles; (3) the need to minimize exposure to radiation, particularly among women of reproductive age; and (4) a high prevalence of nonobstructive CAD and CMD, which are not benign phenotypes, but instead, increasingly recognized to be associated with significant cardiovascular morbidity and mortality.89,90
Risk Stratification of Women with PET MPI
Quantification of Coronary Blood Flow and Reserve
These findings collectively highlight the morbidity associated with diffuse atherosclerosis and CMD. Indeed, even in the setting of normal PET MPI (e.g., no flow-limiting CAD), impaired CFR adds important prognostic value. In a lower risk cohort of symptomatic patients with normal semi-quantitative MPI by PET and less severely reduced CFR, CFR but not sex was independently associated with major adverse cardiovascular events.114 That is, both women and men with CMD (CFR <2 in the presence of normal MPI) experienced worse outcomes, although this phenotype was twice as prevalent in women as in men. This result was consistent even in patients with a CAC score of 0,114 and global CFR, but not CAC, provided significant incremental risk stratification over clinical risk score for prediction of major adverse CAD events.115 Thus, symptomatic patients who do not demonstrate ischemia associated with flow-limiting CAD may have diffuse atherosclerosis and CMD for which a more sensitive, quantitative assessment of ischemia may better diagnose abnormalities and identify novel targets for systemic therapies. Although this is not a uniquely female disorder, this pattern of abnormalities may be especially relevant in certain subsets of women, including those with diabetes and/or metabolic syndrome, low-detectable levels of cardiac troponin,116 heart failure with preserved LVEF (HFpEF),117 atrial fibrillation, and those following chemotherapy and radiation from breast cancer or Hodgkin’s lymphoma, respectively.
Novel Cardiac PET Applications
Finally, the clinical indications for cardiac PET imaging in women extend beyond coronary blood flow to molecular and cellular events in the myocardium. Examples of this include the use of fluorine-18 (18F)-fluorodeoxyglucose (FDG) PET in the evaluation of hibernating myocardium in patients with ischemic cardiomyopathy,118 and in the evaluation of inflammatory infiltrate in patients with suspected or known cardiac sarcoidosis.119
PET Summary Statement
Quantitative PET holds the potential to elucidate the distinct pathophysiology of IHD in women, while also improving diagnostic accuracy and reducing patient exposure to radiation relative to traditional approaches. As such, PET MPI represents a significant contribution to the patient-centered evaluation of myocardial ischemia across the various CAD phenotypes prevalent in both women and men.
MPI as Gatekeeper to Quality Testing Patterns in Women: Focus on Test Efficiency, Cost Effectiveness, and Radiation Dose Reduction
A core component of appropriate identification of patients and the ensuing test-driven strategies must include consideration of costs associated with the diagnostic episode of care. Critical cost issues for cardiovascular imaging include layered or sequential testing patterns as well as the cost consequences of comparative testing patterns over both the near- and long-term duration of care.120 The appropriate selection of patients can markedly reduce the need for additional testing, largely through eliminating testing for those with rarely appropriate indications.121
Test Efficiency and Cost Effectiveness of MPI in Women
Few studies examine the cost efficiency or cost effectiveness of MPI, with even less focusing on women. A large observational study of 11,372 patients with stable angina revealed that a selective ischemia-driven approach using SPECT MPI prior to invasive coronary angiography provided substantial cost savings without significant differences in clinical outcomes compared to a strategy of direct invasive coronary angiography.122 A subanalysis of 4,638 women from this study demonstrated that MPI followed by selective angiography minimized near-term costs compared to direct invasive coronary angiography regardless of pretest likelihood of CAD.123 A similar analysis was reported and projected additional cost savings associated with PET MPI compared with SPECT MPI.124 In another observational registry of 9,521 symptomatic women, exercise SPECT MPI provided incremental cost effectiveness compared to echocardiography among women with established CAD, or women at high risk of CAD events (≥2% annual risk).125
The WOMEN trial evaluated the cost efficiency of exercise SPECT MPI versus ETT in women with low to intermediate risk.15 In this randomized trial, 824 symptomatic women with low-intermediate pretest likelihood of IHD and a Duke Activity Status Index of ≥5 metabolic equivalents (METS) were randomized to a strategy of ETT alone or ETT with SPECT MPI. An initial diagnostic strategy of ETT alone resulted in a similar 2-year outcome of major adverse CAD events (CAD death, hospitalization for an acute coronary syndrome, or heart failure), and 48% diagnostic cost savings (P < 0.001) compared to exercise MPI.15
In a related example, the National Heart, Lung, and Blood Institute (NHLBI)-sponsored Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial evaluated 10,003 patients (52.7% women) randomized to stress testing (67.3% with stress SPECT MPI) or CCTA with the results reporting similar rates of adverse events (death, acute coronary syndromes, or procedural complications) by randomized test strategy (P = 0.75).126 In this trial, the cumulative 3-year costs were similar for patients randomized to stress testing versus CCTA.127 Although the estimated cost of index testing with CCTA was lower than that with an initial functional strategy (including ETT alone, stress MPI, or stress echocardiography), CCTA use was associated with more downstream catheterizations and revascularizations, leading to similar costs averaged over follow-up time. These results have implications for the largely community-based enrollment of the PROMISE trial, where 3-year costs were similar across diagnostic test modalities and support similar evaluation and care costs for a functional versus anatomical testing strategy in a heterogeneous population of patients with suspected CAD. However, given the high prevalence of nonobstructive CAD in symptomatic women,128 and the higher rate of invasive coronary angiography for CCTA in the PROMISE trial, more research is warranted to determine the added contribution of detecting flow-limiting atherosclerotic plaques or small-vessel ischemia. This underscores the critical need for randomized and comparative trial data in female patients.
Radiation Dose Reduction with MPI in Women
Typical radiation exposure, as measured by effective dose, from rest-stress MPI, CCTA, and angiography in women.
Adapted with permission5
Typical radiation exposure (by Effective Dose) from cardiac imaging in women
Effective dose, mSv
Annual background exposure
Invasive coronary angiography
Rest-stress MPI SPECT
Dual-isotope MPI SPECT—should be avoided
Technetium Tc 99m (NaI camera)
Technetium Tc 99m (CZT camera)
Stress-only MPI SPECT
Rest-stress MPI PET
With dose-reduction techniques
Coronary artery calcium scoring
Methods to reduce radiation exposure: Patient testing
The exposure to radiation of patients undergoing a medical diagnostic evaluation is justified only in the setting of appropriate procedural use and optimized dose-reduction strategies. With regard to the former, issues regarding radiation exposure are dependent on the clinical benefit of testing and the evidentiary standards supporting the clinical indication for testing. To reduce unnecessary testing and radiation exposure, the ACC’s AUC or the American College of Radiology’s Appropriateness Criteria, as detailed above, provide primary means for justification of procedural use.9,16 Data suggest that performing testing in patients outside these accepted criteria (rarely appropriate) results in a very low diagnostic yield, as the vast percentage of studies is normal.140,141 Thus, the principal means of reducing radiation exposure among women is to restrict utilization of MPI to those meeting appropriate indications for testing.
With regard to the latter, minimizing radiation exposure for patients is of considerable importance for optimal patient safety, regardless of sex. All clinicians involved in the patient’s care must be involved in this process, from the healthcare provider ordering the test to the nuclear cardiologist performing and interpreting the test, to whom responsibility ultimately falls for selecting testing protocols, equipment, and tracers. ASNC has advocated that the median patient dose per study should be <9 millisieverts (mSv).132 The next section will highlight specific methods to reduce radiation dose, such as the use of stress-only imaging or the expanded application of cardiac PET MPI, to aid any laboratory in achieving ASNC goals. Recent worldwide surveys from the International Atomic Energy Agency-sponsored (IAEA) Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS) registry suggest that there is considerable room for improvement in radiation dose-reduction practices for both women and men.142 From the INCAPS registry, including 7,911 patients from 65 countries, mean effective dose was slightly lower for women (9.6 mSv) as compared to men (10.3 mSv; P < 0.001). While stress-only MPI was performed more often in women than in men (12.5% versus 8.4%; P < 0.001), camera-based dose-reduction strategies were used less frequently in women than in men (59% versus 66%; P < 0.0001). These data support that additional improvements in radiation dose reduction are possible for both women and men.
Methods to reduce radiation exposure: Imaging protocols
The most widely utilized tracers are 99mTc based, with a typical rest/stress protocol resulting in an effective dose ranging from 8 to 16 mSv. By comparison, MPI protocols involving 201Tl are in the 11 to 23 mSv range.143 Because of this increased exposure to ionizing radiation without added benefit in diagnostic or prognostic accuracy, the use of 201Tl or dual-isotope (rest: 201Tl/stress: 99mTc) protocols is discouraged for most patients by ASNC consensus statements.139,143 Nonetheless, surveys indicate that 201Tl remains an isotope commonly utilized in the United States.144, 145, 146, 147, 148 An immediate method to reduce radiation exposure, therefore, is to eliminate 201Tl use as a primary imaging tracer in all laboratories, as recommended by ASNC.139
Stress-only or stress-first imaging
In most laboratories, a patient undergoes the rest study first, followed by stress, despite data that only 9% to 34% of studies performed are positive for ischemia or infarction.149,150 Thus, performing the stress as the initial imaging study (particularly with attenuation correction techniques), and the rest only when needed may be a reasonable means of increasing laboratory efficiency and reducing patient radiation exposure in the appropriately selected patient. Regardless of whether the initial stress dose is high (24 to 30 millicuries, mCi) or low (8 to 12 mCi), substantial radiation reduction is achieved by avoidance of the rest study.62,151, 152, 153, 154, 155, 156, 157 Despite the overwhelming data supporting stress before rest, currently only a small proportion of laboratories are using this protocol.14,142,144
Image processing and software for existing systems
New advances have demonstrated that using software to enhance image quality for existing cameras can also reduce radiation exposure by decreasing isotope dosage by approximately 25%-75%.80,158,159 Replacement of filtered back projection with iterative reconstruction (ordered subset expectation minimization, OSEM) potentially requires 25% to 75% less counts to produce similar images.160 Wide-beam reconstruction and similar software solutions compensate for the complicated beam angles and spread of counts when reconstructing the image, and can achieve high-image quality with reduced radiation.161 Algorithms that combine multiple levels of processing by utilizing OSEM, noise reduction algorithms, collimator design, scatter modeling, and attenuation correction can produce high-quality images during half-time acquisition. Data from a variety of studies have demonstrated that these applications result in excellent image quality with per-patient radiation exposure in the range of 4 to 8 mSv.80,158
New camera systems
Consideration for potential radiation reduction should be a factor when purchasing new equipment. In contrast to standard Anger sodium iodine (NaI) cameras, new solid-state detectors have been developed which utilize CZT arrays. Data suggest that higher count sensitivity of CZT cameras can produce images of comparable diagnostic quality with 15% to 30% of standard radiation doses.162, 163, 164 Ultra-low-dose protocols involving the use of stress-first imaging in appropriately selected patients with CZT cameras have led to substantial reductions in effective radiation exposure, to as low as 1 mSv per study.165,166
PET MPI to reduce radiation exposure
A major strength of PET imaging, especially for the evaluation of the female patient, is that enhanced image quality and diagnostic capability are feasible while limiting patient exposure to ionizing radiation. Rest/stress perfusion imaging using the PET radiopharmaceuticals 82Rb or nitrogen-13 (13N) ammonia, with half-lives of 1.2 and 9.8 minutes, respectively, results in an effective dose of radiation at or below annual background exposure levels (≤3 mSv) (Table 2).5 This is significantly lower than that associated with a rest/stress conventional SPECT study using 99mTc (≈11 mSv) or with diagnostic invasive coronary angiography (≈7 mSv), and commensurate with ALARA principles as recommended by the Joint Commission on Diagnostic Imaging for cardiac imaging procedures.129,167
Strategies for reducing radiation exposure in women undergoing radionuclide myocardial perfusion imaging
1. Use AUC to guide patient selection for nuclear cardiology procedures.
2. Use technetium-based tracers for SPECT MPI studies. Avoid use of thallium-based and dual-isotope SPECT protocols.
3. Consider stress-first MPI (especially with attenuation correction techniques) for select patients without evidence of prior MI or cardiomyopathy.
4. Implement iterative reconstruction algorithms for use with existing SPECT technology.
5. Use high-sensitivity solid-state CZT SPECT cameras and/or PET MPI where available.
6. Continually review nuclear laboratory practices to implement dose-reduction strategies to decrease patient radiation doses to levels that are as low as reasonably achievable (ALARA) and approaching levels of natural background radiation (3 mSV/year) whenever possible.
Comparative Trial Evidence of MPI versus Other Approaches in SIHD
There have been numerous randomized trials of imaging in the evaluation of suspected SIHD published in the last several years, many of which included the use of stress MPI imaging.15,168, 169, 170 As already briefly described, the WOMEN trial randomized 824 symptomatic women to a strategy of index exercise ECG versus exercise SPECT MPI.15 At 2 years of follow-up, there were no differences in the rate of CAD death, MI, or hospitalization for acute coronary syndromes or heart failure (1.7% in the exercise ECG arm versus 2.3% in the exercise SPECT MPI arm, P = 0.59). Nearly 1 in 5 women randomized to the exercise ECG arm had a follow-up SPECT MPI scan, largely, for those with indeterminate or positive test results. Findings from this trial revealed that a first strategy of exercise ECG followed by selective SPECT MPI can effectively manage low-risk women. Sizeable cost savings were achieved using this approach of the exercise ECG first compared to index SPECT MPI testing, with a cost savings for the diagnostic evaluation of approximately $300 (P < 0.0001).
In a secondary analysis from the single-center Clinical Evaluation of MAgnetic Resonance imaging in Coronary heart disease (CE-MARC) trial, 235 women underwent adenosine SPECT MPI, a multiparametric cardiovascular magnetic resonance imaging (CMR) examination (including balanced steady-state free precession cine imaging, rest/stress perfusion, 3D CMR angiography, and late gadolinium enhancement), and invasive coronary angiography.168,171 The results indicated a sensitivity and specificity for SPECT MPI of 59% and 84% versus 89% and 84% for the multiparametric CMR (P < 0.0001 and P = 0.77, respectively. This higher accuracy of CMR is likely attributable to single-site expertise, but requires further validation with a comprehensive nuclear examination, which is considered the standard of care in diagnostic testing. In a related example from the PROMISE trial, community-based interpretation of stress test findings (67% stress MPI) resulted in a 2.1-year rate of death, MI, or hospitalization for unstable angina of 5.1% and 1.9% for women with positive and negative stress-test findings (P < 0.0001).169,170 These data support that a multicenter, community-based interpretation can effectively stratify risk in women, a strong statement for the accuracy of MPI testing across the United States.
Several recent randomized trials have compared stress testing approaches to CCTA strategies of care, revealing no statistically significant difference in outcome over the nearly 2 years of follow-up for both the Scottish COmputed Tomography of the HEART (SCOT-HEART) and PROMISE trials.126,172 This supports that contemporary diagnostic testing practices including MPI are effective for evaluating patients with SIHD. Findings from these two trials revealed a lower rate of follow-up invasive angiography in those undergoing stress testing; which was performed prior to randomization in 85% of patients in the SCOT-HEART trial. For example, in the PROMISE trial, the rate of invasive coronary angiography was 12.2% in the CCTA arm and 8.1% in the stress testing arm (P = 0.022). Moreover, the rate of coronary revascularization was nearly twofold higher in the CCTA arm as compared to the stress testing arm within the PROMISE trial (6.2% versus 3.2%). Although stress testing included evaluations with and without imaging, these data support the use of functional testing approaches as gatekeepers to invasive angiography and selective revascularization, and are consistent with ischemia-guided management. In a secondary analysis from the PROMISE trial, no difference in the primary outcome was observed by randomization for women (P = 0.75) or men (P = 0.76).169,173
Recently, the CE-MARC 2 trial provided further evidence for the comparative effectiveness of CMR versus SPECT MPI.174 In 1,202 symptomatic patients (46.9% women) with a mean pretest likelihood of 49.5%, reduction in unnecessary angiography when compared to the National Institute of Health and Care Excellence (NICE) guidelines was similarly low with SPECT (16.2% [95% CI, 13.0% to 19.8%] as well as CMR (17.7% [95% CI, 14.4% to 21.4%]).175
It is important to note that enrollment of women in clinical trials and in clinical research in general is often lower than optimal. The recent studies highlighted above serve to remind the scientific community of the importance of active recruitment of women into clinical trials. Doing so may allow sex-specific data to become available and to facilitate identification of potentially unique differences among women and men, depending on the specifics of trial or registry design. Women-only trials in SIHD should also be encouraged, especially for those phenotypes that appear to be particularly prevalent in women, including symptomatic nonobstructive CAD and HFpEF.
Future Directions: SIHD Without Obstructive CAD
IHD poses a major threat to women across their lifespans, and we are only beginning to recognize the importance of expanding conventional tools developed more than a half-century ago for the diagnosis and management of (primarily obstructive) CAD, to IHD in women. Women with ongoing chest pain due to either obstructive or nonobstructive coronary disease have increased mortality compared to asymptomatic patients with disease. This updated consensus statement provides a state-of-the-art review on the available evidence of the role of MPI for the evaluation of stable IHD in symptomatic women.
This work was supported in part by K12 HD051959 Building Interdisciplinary Research Careers in Women’s Health and a Harvard Medical School Diversity Partnership Faculty Fellowship to Dr Taqueti.
Dr. Sharmila Dorbala receives grant support from Astellas Pharma and has investment in General Electric stocks. Dr. David Wolinsky receives grant support from Astellas Pharma, serves on the speakers’ bureau of Astellas Pharma and the steering committee for Adenosine Therapeutics. Dr. Gary V. Heller receives royalties from McGraw Hill and is a consultant to Morristown Medical Center. Dr. Heller is a medical advisor to Molecular Imaging Services and a research officer for the nonprofit group, Intersocietal Accreditation Commission. Dr. Timothy Bateman receives royalties from ExSPECT II attenuation correction, ImagenPro/MD/Q/3D, and support from Astellas Pharma and GE Healthcare. Dr. Bateman is on the advisory board for Lantheus Medical Imaging and is the medical director of Cardiovascular Imaging Technologies, LLC. Dr. Lawrence Phillips receives consulting fees from Merck, Inc. All other contributors have nothing relevant to disclose.
- 7.Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44-164.PubMedCrossRefGoogle Scholar
- 8.Mieres JH, Shaw LJ, Hendel RC, Miller DD, Bonow RO, Berman DS, et al. American Society of Nuclear Cardiology consensus statement: Task force on women and coronary artery disease—the role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women [correction]. J Nucl Cardiol 2003;10:95-101.PubMedCrossRefGoogle Scholar
- 9.Wolk MJ, Bailey SR, Doherty JU, Douglas PS, Hendel RC, Kramer CM, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014;63:380-406.PubMedCrossRefGoogle Scholar
- 11.Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:12.Google Scholar
- 14.Hendel RC, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, Pellikka PA, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. Circulation 2009;119:e561-87.PubMedCrossRefGoogle Scholar
- 15.Shaw LJ, Mieres JH, Hendel RH, Boden WE, Gulati M, Veledar E, et al. Comparative effectiveness of exercise electrocardiography with or without myocardial perfusion single photon emission computed tomography in women with suspected coronary artery disease: Results from the What Is the Optimal Method for Ischemia Evaluation in Women (WOMEN) trial. Circulation 2011;124:1239-49.PubMedCrossRefGoogle Scholar
- 19.Dolor RJ, Patel MR, Melloni C, Chatterjee R, McBroom AJ, Musty MD, et al. Noninvasive technologies for the diagnosis of coronary artery disease in women Rockville (MD): AHRQ Comparative Effectiveness Reviews 2012;Report No.: 12-EHC034-EF.Google Scholar
- 20.Sanders GD, Patel MR, Chatterjee R, Ross AK, Bastian LA, Coeytaux RR, et al. Noninvasive technologies for the diagnosis of coronary artery disease in women: Identification of future research needs from comparative effectiveness review No 58. Rockville (MD): AHRQ comparative effectiveness reviews 2013; Report No.: 13-EHC072-EF.Google Scholar
- 21.Sharir T, Kang X, Germano G, Bax JJ, Shaw LJ, Gransar H, et al. Prognostic value of poststress left ventricular volume and ejection fraction by gated myocardial perfusion SPECT in women and men: Gender-related differences in normal limits and outcomes. J Nucl Cardiol 2006;13:495-506.PubMedCrossRefGoogle Scholar
- 22.Rivero A, Santana C, Folks RD, Esteves F, Verdes L, Esiashvili S, et al. Attenuation correction reveals gender-related differences in the normal values of transient ischemic dilation index in rest-exercise stress sestamibi myocardial perfusion imaging. J Nucl Cardiol 2006;13:338-44.PubMedCrossRefGoogle Scholar
- 29.Berman DS, Kang X, Nishina H, Slomka PJ, Shaw LJ, Hayes SW, et al. Diagnostic accuracy of gated Tc-99m sestamibi stress myocardial perfusion SPECT with combined supine and prone acquisitions to detect coronary artery disease in obese and nonobese patients. J Nucl Cardiol 2006;13:191-201.PubMedCrossRefGoogle Scholar
- 32.Grossman GB, Garcia EV, Bateman TM, Heller GV, Johnson LL, Folks RD, et al. Quantitative Tc-99m sestamibi attenuation-corrected SPECT: Development and multicenter trial validation of myocardial perfusion stress gender-independent normal database in an obese population. J Nucl Cardiol 2004;11:263-72.PubMedCrossRefGoogle Scholar
- 34.Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 2010;55:2825-32.PubMedPubMedCentralCrossRefGoogle Scholar
- 35.Taqueti V, Shaw LJ, Murthy VL, Shah NR, Foster CR, Hainer J, et al. Excess cardiovascular risk in women relative to men referred for coronary angiography is associated with impaired coronary flow reserve from diffuse versus obstructive coronary artery disease. Circulation 2017;135:566-77.PubMedCrossRefGoogle Scholar
- 37.Grzybowski A, Puchalski W, Zieba B, Gruchala M, Fijalkowski M, Storoniak K, et al. How to improve noninvasive coronary artery disease diagnostics in premenopausal women? The influence of menstrual cycle on ST depression, left ventricle contractility, and chest pain observed during exercise echocardiography in women with angina and normal coronary angiogram. Am Heart J 2008;156:964 e1-5.CrossRefGoogle Scholar
- 46.Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Investigators A-MT. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16.CrossRefGoogle Scholar
- 70.Ramakrishna G, Miller TD, Breen JF, Araoz PA, Hodge DO, Gibbons RJ. Relationship and prognostic value of coronary artery calcification by electron beam computed tomography to stress-induced ischemia by single photon emission computed tomography. Am Heart J 2007;153:807-14.PubMedCrossRefGoogle Scholar
- 71.Einstein AJ, Johnson LL, Bokhari S, Son J, Thompson RC, Bateman TM, et al. Agreement of visual estimation of coronary artery calcium from low-dose CT attenuation correction scans in hybrid PET/CT and SPECT/CT with standard Agatston score. J Am Coll Cardiol 2010;56:1914-21.PubMedPubMedCentralCrossRefGoogle Scholar
- 72.Lubbers M, Dedic A, Coenen A, Galema T, Akkerhuis J, Bruning T, et al. Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: The multicentre, randomized CRESCENT trial. Eur Heart J 2016;37:1232-43.PubMedCrossRefGoogle Scholar
- 78.Husmann L, Herzog BA, Gaemperli O, Tatsugami F, Burkhard N, Valenta I, et al. Diagnostic accuracy of computed tomography coronary angiography and evaluation of stress-only single-photon emission computed tomography/computed tomography hybrid imaging: Comparison of prospective electrocardiogram-triggering vs. retrospective gating. Eur Heart J 2009;30:600-7.PubMedCrossRefGoogle Scholar
- 83.Chowdhury FU, Vaidyanathan S, Bould M, Marsh J, Trickett C, Dodds K, et al. Rapid-acquisition myocardial perfusion scintigraphy (MPS) on a novel gamma camera using multipinhole collimation and miniaturized cadmium-zinc-telluride (CZT) detectors: Prognostic value and diagnostic accuracy in a ‘real-world’ nuclear cardiology service. Eur Heart J Cardiovasc Imaging 2014;15:275-83.PubMedCrossRefGoogle Scholar
- 89.Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, et al. Insights from the NHLBI-sponsored women’s ischemia syndrome evaluation (WISE) study: Part II: Gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006;47:S21-9.PubMedCrossRefGoogle Scholar
- 90.Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the NHLBI-sponsored women’s ischemia syndrome evaluation (WISE) study: Part I: GENDER differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47:S4-20.PubMedCrossRefGoogle Scholar
- 93.Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol 2008;15:745-53.PubMedCrossRefGoogle Scholar
- 97.Kay J, Dorbala S, Goyal A, Fazel R, Di Carli MF, Einstein AJ, et al. Influence of sex on risk stratification with stress myocardial perfusion Rb-82 positron emission tomography: Results from the PET (Positron Emission Tomography) Prognosis Multicenter Registry. J Am Coll Cardiol 2013;62:1866-76.PubMedCrossRefGoogle Scholar
- 98.Dorbala S, Vangala D, Sampson U, Limaye A, Kwong R, Di Carli MF. Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocardium at risk and the extent of angiographic coronary artery disease: A 82Rb PET/CT study. J Nucl Med 2007;48:349-58.PubMedGoogle Scholar
- 100.Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw LJ, Handberg EM, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: A report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med 2009;169:843-50.PubMedPubMedCentralCrossRefGoogle Scholar
- 102.von Mering GO, Arant CB, Wessel TR, McGorray SP, Bairey Merz CN, Sharaf BL, et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: Results from the national heart, lung, and blood institute-sponsored women’s ischemia syndrome evaluation (WISE). Circulation 2004;109:722-5.CrossRefGoogle Scholar
- 111.Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation 2015;131:19-27.PubMedCrossRefGoogle Scholar
- 121.Lee AJ, Michail M, Quaderi SA, Richardson JA, Aggarwal SK, Speechly-Dick ME. Implementation of NICE clinical guideline 95 for assessment of stable chest pain in a rapid access chest pain clinic reduces the mean number of investigations and cost per patient. Open Heart 2015;2:e000151.PubMedPubMedCentralCrossRefGoogle Scholar
- 122.Shaw LJ, Hachamovitch R, Berman DS, Marwick TH, Lauer MS, Heller GV, et al. The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: An observational assessment of the value of precatheterization ischemia. Economics of noninvasive diagnosis (END) multicenter study group. J Am Coll Cardiol 1999;33:661-9.PubMedCrossRefGoogle Scholar
- 138.Gerber TC, Carr JJ, Arai AE, Dixon RL, Ferrari VA, Gomes AS, et al. Ionizing radiation in cardiac imaging: a science advisory from the American Heart Association Committee on Cardiac Imaging of the Council on Clinical Cardiology and Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention. Circulation 2009;119:1056-65.PubMedCrossRefGoogle Scholar
- 141.Doukky R, Hayes K, Frogge N. Appropriate use criteria for SPECT myocardial perfusion imaging: Are they appropriate for women? J Nucl Cardiol 2015.Google Scholar
- 146.Mercuri M, Pascual TN, Mahmarian JJ, Shaw LJ, Rehani MM, Paez D, et al. Comparison of radiation doses and best-practice use for myocardial perfusion imaging in US and non-US Laboratories: Findings from the IAEA (International Atomic Energy Agency) nuclear cardiology protocols study. JAMA Intern Med 2016;176:266-9.PubMedCrossRefGoogle Scholar
- 147.Einstein AJ, Tilkemeier P, Fazel R, Rakotoarivelo H, Shaw LJ, American Society of Nuclear C. Radiation safety in nuclear cardiology-current knowledge and practice: Results from the 2011 American Society of Nuclear Cardiology member survey. JAMA Intern Med 2013;173:1021-3.PubMedCrossRefGoogle Scholar
- 151.Mahmarian JJ. Implementation of stress-only imaging: What will it take? J Nucl Cardiol 2015.Google Scholar
- 154.Pazhenkottil AP, Kaufmann PA, Gaemperli O. Attenuation correction in stress-only myocardial perfusion imaging. J Nucl Cardiol 2016.Google Scholar
- 160.DePuey EG, Gadiraju R, Clark J, Thompson L, Anstett F, Shwartz SC. Ordered subset expectation maximization and wide beam reconstruction “half-time” gated myocardial perfusion SPECT functional imaging: A comparison to “full-time” filtered backprojection. J Nucl Cardiol 2008;15:547-63.PubMedCrossRefGoogle Scholar
- 161.Venero CV, Heller GV, Bateman TM, McGhie AI, Ahlberg AW, Katten D, et al. A multicenter evaluation of a new post-processing method with depth-dependent collimator resolution applied to full-time and half-time acquisitions without and with simultaneously acquired attenuation correction. J Nucl Cardiol 2009;16:714-25.PubMedCrossRefGoogle Scholar
- 162.Einstein AJ, Blankstein R, Andrews H, et al. Comparison of image quality, myocardial perfusion, and left ventricular function between standard imaging and single-injection ultra-low-dose imaging using a high-efficiency SPECT camera: The MILLISIEVERT study. J Nucl Med 2014;55:1430-7.PubMedPubMedCentralCrossRefGoogle Scholar
- 165.Einstein AJ, Blankstein R, Andrews H, et al. Comparison of image quality, myocardial perfusion, and left ventricular function between standard imaging and single-injection ultra-low-dose imaging using a high-efficiency SPECT camera: The MILLISIEVERT study. J Nucl Med 2014;55:1430-7.PubMedPubMedCentralCrossRefGoogle Scholar
- 166.Thompson RC, O’Keefe JH, McGhie AI, Bybee KA, Thompson EC, Bateman TM. Reduction of SPECT MPI radiation dose using contemporary protocols and technology. JACC Cardiovasc Imaging 2017; 2259.Google Scholar
- 167.The Joint Commission. Diagnostic imaging standards. Published August 10, 2015. https://www.jointcommission.org/assets/1/18/AHC_DiagImagingRpt_MK_20150806.pdf. Accessed March 6, 2017.
- 168.Greenwood JP, Motwani M, Maredia N, Brown JM, Everett CC, Nixon J, et al. Comparison of cardiovascular magnetic resonance and single-photon emission computed tomography in women with suspected coronary artery disease from the clinical evaluation of magnetic resonance imaging in coronary heart disease (CE-MARC) Trial. Circulation 2014;129:1129-38.PubMedCrossRefGoogle Scholar
- 170.Hemal K, Pagidipati NJ, Coles A, Dolor RJ, Mark DB, Pellikka PA, et al. Sex differences in demographics, risk factors, presentation, and noninvasive testing in stable outpatients with suspected coronary artery disease: Insights from the PROMISE trial. JACC Cardiovasc Imaging 2016;9:337-46.PubMedPubMedCentralCrossRefGoogle Scholar
- 173.Hemal K, Pagidipati NJ, Coles A, Dolor RJ, Mark DB, Pellikka PA, et al. Sex differences in demographics, risk factors, presentation, and noninvasive testing in stable outpatients with suspected coronary artery disease: Insights from the PROMISE trial. JACC Cardiovasc Imaging 2016;9:337-46.PubMedPubMedCentralCrossRefGoogle Scholar
- 174.Ripley DP, Brown JM, Everett CC, Bijsterveld P, Walker S, Sculpher M, et al. Rationale and design of the clinical evaluation of magnetic resonance imaging in coronary heart disease 2 trial (CE-MARC 2): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease. Am Heart J 2015;169:17-24 e1.Google Scholar
- 175.Greenwood JP, Ripley DP, Berry C, McCann GP, Plein S, Bucciarelli-Ducci C, et al. Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: The CE-MARC 2 randomized clinical trial. JAMA 2016;316:1051-60.PubMedCrossRefGoogle Scholar
- 178.Johnson BD, Shaw LJ, Pepine CJ, Reis SE, Kelsey SF, Sopko G, et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored women’s ischaemia syndrome evaluation (WISE) study. Eur Heart J 2006;27:1408-15.PubMedCrossRefGoogle Scholar
- 181.Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): Impact on angina and myocardial perfusion reserve. Eur Heart J 2016;37:1504-13.PubMedCrossRefGoogle Scholar